Evaluation of 12-lipoxygenase (12-LOX) and plasminogen activator inhibitor 1 (PAI-1) as prognostic markers in prostate cancer.
In carcinoma of prostate, a causative role of platelet 12-lipoxygenase (12-LOX) and plasminogen activator inhibitor 1 (PAI-1) for tumor progression has been firmly established in tumor and/or adjacent tissue. Our goal was to investigate if 12-LOX and/or PAI-1 in patient's plasma could be used to predict outcome of the disease. The study comprised 149 patients (age 70±9) divided into two groups: a study group with carcinoma confirmed by positive biopsy of prostate (n=116) and a reference group (n=33) with benign prostatic hyperplasia (BPH). The following parameters were determined by the laboratory test in plasma or platelet-rich plasma: protein level of 12-LOX, PAI-1, thromboglobulin (TGB), prostate specific antigen (PSA), C-reactive protein (CRP), hemoglobin (HGB, and hematocrit (HCT), as well as red (RBC) and white blood cells (WBC), number of platelets (PLT), international normalized ratio of blood clotting (INR), and activated partial thromboplastin time (APTT). The only difference of significance was noticed in the concentration of 12-LOX in platelet rich plasma, which was lower in cancer than in BPH group. Standardization to TGB and platelet count increases the sensitivity of the test that might be used as a biomarker to assess risk for prostate cancer in periodically monitored patients.
Department of Urology, St' Vincent A Paulo Hospital, Wójta Radtkego 1, 81-348 Gdynia, Poland ; Department of Urology, Multidisciplinary Hospital Jantar, Rybacka 15, 82-103 Jantar, Poland.
Tomasz
T
Gondek
Department of Surgical Oncology, Gdynia Oncology Center, PCK's Maritime Hospital in Gdynia, Powstania Styczniowego 1, 81-519 Gdynia, Poland ; Department of Propaedeutic Oncology, Faculty of Health Sciences, Medical University of Gdańsk, Powstania Styczniowego 9b, 81-519 Gdynia, Poland.
Mariusz
M
Szajewski
Department of Surgical Oncology, Gdynia Oncology Center, PCK's Maritime Hospital in Gdynia, Powstania Styczniowego 1, 81-519 Gdynia, Poland ; Department of Propaedeutic Oncology, Faculty of Health Sciences, Medical University of Gdańsk, Powstania Styczniowego 9b, 81-519 Gdynia, Poland.
Jarosław
J
Szefel
Department of Clinical Nutrition, Medical University of Gdańsk, Dębinki 7, 80-211 Gdańsk, Poland.
Ewa
E
Aleksandrowicz-Wrona
Urology Research Center, Department of Urology, The University of Toledo, Health Science Campus, Toledo, OH 43614, USA.
Ewa
E
Skrzypczak-Jankun
Department of Clinical Nutrition, Medical University of Gdańsk, Dębinki 7, 80-211 Gdańsk, Poland ; Urology Research Center, Department of Urology, The University of Toledo, Health Science Campus, Toledo, OH 43614, USA ; Protein Research Chair, Department of Biochemistry, College of Sciences, King Saud University, Riyadh 11451, Saudi Arabia.
Jerzy
J
Jankun
Department of Clinical Nutrition, Medical University of Gdańsk, Dębinki 7, 80-211 Gdańsk, Poland ; Powiślanski College, Faculty of Health Science, 11 Listopada 13, 82-500 Kwidzyń, Poland.
Wieslawa
W
Lysiak-Szydlowska
D000368:Aged; D001092:Arachidonate 12-Lipoxygenase / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D008297:Male; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood* / Q000175:diagnosis*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; D001092:Arachidonate 12-Lipoxygenase